Zureik Abir, Couturier Aude, Delcourt Cécile
Ophthalmology Department, AP-HP, Hôpital Lariboisière, Université Paris Cité, 2 Rue Ambroise Paré, 75010, Paris, France.
University Bordeaux, INSERM, BPH, U1219, F-33000, Bordeaux, France.
Graefes Arch Clin Exp Ophthalmol. 2025 Mar 17. doi: 10.1007/s00417-025-06793-x.
The aim of this study is to describe ophthalmological care of adults with diabetes in France and its evolution between 2010 and 2022.
In this study, we used the ESND, a representative permanent random sample of 2/100th of the entire French population. Ophthalmological care was defined by the combination of ophthalmological procedures (fundus examination, color fundus photography, Optical Coherence Tomography..) and/or ophthalmological treatment (intravitreal injection or laser treatment) during the year. Changes in annual rates during the study period were assessed using linear regression models excluding 2020.
From 2010 to 2022, the number of adults treated for diabetes in the ENSD increased from 48 329 patients (mean age 65.3 ± 13.0, 46.3% women) to 68 397 patients (mean age 67.0 ± 13.2, 44.8% women). Among them, the annual rate of ophthalmological care was stable (46.5% in 2010 and 48.5% in 2022) and the difference was not significant (β = 0.10% per year, p = 0.11). The yearly ophthalmological treatment rate increased significantly (3.3% in 2010 and 5.3% in 2022, β = 0.2% per year, p < 0.0001). Rates were lower during the COVID-19 outbreak in 2020.Women, individuals aged between 66-80 years, those living in the least deprived areas and those treated with combined insulin and non-insulin treatment had higher yearly ophthalmological care rate.
In this large nationwide representative study with recent and updated data, although ophthalmological treatment rate has increased over the decade mainly due to intravitreal injections, less than half of the diabetic patients receive yearly ophthalmological care.
本研究旨在描述法国成年糖尿病患者的眼科护理情况及其在2010年至2022年间的变化。
在本研究中,我们使用了ESND,这是一个对法国全体人口进行1/50抽样的代表性永久随机样本。眼科护理通过当年眼科程序(眼底检查、彩色眼底摄影、光学相干断层扫描等)和/或眼科治疗(玻璃体内注射或激光治疗)的组合来定义。使用排除2020年的线性回归模型评估研究期间年率的变化。
从2010年到2022年,ESND中接受糖尿病治疗的成年人数从48329例患者(平均年龄65.3±13.0岁,46.3%为女性)增加到68397例患者(平均年龄67.0±13.2岁,44.8%为女性)。其中,眼科护理的年率保持稳定(2010年为46.5%,2022年为48.5%),差异不显著(β=每年0.10%,p=0.11)。每年的眼科治疗率显著增加(2010年为3.3%,2022年为5.3%,β=每年0.2%,p<0.0001)。2020年新冠疫情期间的治疗率较低。女性、年龄在66 - 80岁之间的个体、生活在最不贫困地区的个体以及接受胰岛素和非胰岛素联合治疗的个体每年的眼科护理率较高。
在这项拥有最新数据的大型全国代表性研究中,尽管在过去十年中眼科治疗率主要因玻璃体内注射而有所增加,但仍不到一半的糖尿病患者每年接受眼科护理。